Wuhan YZY Biopharma (HKG:2496) obtained clinical trial approval for the investigational new drug application for M701 from the US Food and Drug Administration ( FDA ), according to a Tuesday Hong Kong bourse filing.
The drug is indicated for malignant pleural effusion (MPE), which is a common and severe complication of malignant tumors, particularly in advanced lung and breast cancer patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.